Literature DB >> 30251442

Novel association of Psychrobacter and Pseudomonas with malodour in bloodhound dogs, and the effects of a topical product composed of essential oils and plant-derived essential fatty acids in a randomized, blinded, placebo-controlled study.

Courtney Meason-Smith1, Caitlin E Older1, Roxanna Ocana1, Brandon Dominguez2, Sara D Lawhon1, Jing Wu1, Adam P Patterson3, Aline Rodrigues Hoffmann1.   

Abstract

BACKGROUND: The pathogenesis and treatment of cutaneous malodour in dogs have not been investigated previously. Staphylococcus and Corynebacterium spp. are associated with human axillary malodour. HYPOTHESIS: Staphylococcus and Corynebacterium spp. are associated with cutaneous malodour in dogs, and treatment with a topical essential oil-based product will improve malodour and reduce the abundance of odour-causing bacteria. ANIMALS: Twenty seven bloodhound dogs from a south Texas boarding facility were enrolled in this study. METHODS AND MATERIALS: Skin swabs were taken from the axilla and dorsum of 27 dogs at initiation of the study. Mean malodour scores were used to assign dogs to control or malodour groups. The malodourous dogs were randomly assigned to a treatment or placebo group, received four weekly topical applications of the spot-on or placebo, and samples were recollected. Next-generation sequencing (NGS) and real-time quantitative PCR (qPCR) were performed on all swabs.
RESULTS: Psychrobacter and Pseudomonas spp. were significantly more abundant (P < 0.001, P = 0.006; respectively), and overall bacterial diversity was reduced (P = 0.0384) on the skin of malodourous dogs. Staphylococcus and Corynebacterium spp. were not associated with malodour. The topical essential oil-based product significantly (P = 0.0078) improved malodour in the treatment group and shifted their bacterial community structure. CONCLUSIONS AND CLINICAL IMPORTANCE: A novel association of bacterial genera with malodour in bloodhound dogs, identified by NGS, highlights future targets for odour control. The topical treatment significantly reduced malodour. The interaction between the topical treatment and cutaneous microbiota should be further investigated and may be useful in other dermatological conditions involving microbiota.
© 2018 ESVD and ACVD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30251442     DOI: 10.1111/vde.12689

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  6 in total

1.  Antifungal in vitro Activity of Essential Oils against Clinical Isolates of Malassezia pachydermatis from Canine Ears: A Report from a Practice Laboratory.

Authors:  Doris Bismarck; Anika Dusold; Anton Heusinger; Elisabeth Müller
Journal:  Complement Med Res       Date:  2019-11-27       Impact factor: 1.211

2.  Topical effect of a specific spot-on treatment made of natural ingredients in rabbits (Oryctolagus cuniculus) with skin problems: A pilot study.

Authors:  Galia Sheinberg Waisburd; Alberto Martin Cordero; Camilo Romero Núñez; Laura Miranda Contreras; Rafael Heredia Cárdenas; Linda G Bautista Gómez
Journal:  Vet World       Date:  2020-09-03

3.  Characterization of microbiota diversity of engorged ticks collected from dogs in China.

Authors:  Seongjin Wang; Xiuguo Hua; Li Cui
Journal:  J Vet Sci       Date:  2021-05       Impact factor: 1.672

4.  Microbiota profiling with long amplicons using Nanopore sequencing: full-length 16S rRNA gene and the 16S-ITS-23S of the  rrn operon.

Authors:  Anna Cuscó; Carlotta Catozzi; Joaquim Viñes; Armand Sanchez; Olga Francino
Journal:  F1000Res       Date:  2018-11-06

Review 5.  The skin microbiome of vertebrates.

Authors:  Ashley A Ross; Aline Rodrigues Hoffmann; Josh D Neufeld
Journal:  Microbiome       Date:  2019-05-23       Impact factor: 14.650

Review 6.  Essential Oils and Melatonin as Functional Ingredients in Dogs.

Authors:  Domingo Ruiz-Cano; Ginés Sánchez-Carrasco; Amina El-Mihyaoui; Marino B Arnao
Journal:  Animals (Basel)       Date:  2022-08-16       Impact factor: 3.231

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.